Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP061: Human amnion epithelial cells reduce intestinal inflammation in a 2,4,6-trinitrobenzene sulfonic acid induced model of acute colitisECCO '18 Vienna
Year: 2018
Authors:

N. Kuk1,2*, J. Correia1,2, M. Alhomrani1,2,3, R. Lim3, W. Sievert1,2, A. Hodge1,2, G. Moore1,2

1Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 2Gastroenterology and Hepatology Unit, Monash Medical Centre, Melbourne, Australia, 3Hudson Institute for Medical Research, Melbourne, Australia

DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapyECCO '18 Vienna
Year: 2018
Authors:

G.R. D´Haens1*, K. Gorelick2, Y. Wang3, F. Cataldi3, W.J. Sandborn4

1Academic Medical Centre, Amsterdam, The Netherlands, 2Zymo Consulting Group, Newtown Square, USA, 3Shire, Lexington, USA, 4University of California San Diego, La Jolla, USA

DOP063: Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitisECCO '18 Vienna
Year: 2018
Authors:

L.C. De Vries1,2, M.E. Wildenberg1,2*, R.A. Willemze1,2, H.P. van Hamersveld1, O. Welting1, C. Verseijden1, B. Strobl3, M. Mueller3, G.R. D'Haens2, W.J. De Jonge1

1Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands, 2Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3University of Veterinary Medicine, Institute of Animal Breeding and Genetics, Vienna, Austria

DOP064: ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

G. Doherty1*, K. Katsanos2, J. Burisch3, M. Allez4, K. Papamichael5, A. Stallmach6, R. Mao7, I. Prytz Berset8, J. Gisbert9, S. Sebastian10, J. Kierkuś11, L. Lopetuso12, E. Szymanska11, E. Louis13

1St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 2University and Medical School of Ioannina, Ioannina, Greece, 3North Zealand University Hospital, Frederikssund, Denmark, 4Hôpital Saint-Louis, APHP, INSERM UMRS 1160, Université Denis Diderot, Paris, France, 5Beth Israel Deaconess Medical Center, Department of Gastroenterology, Boston, USA, 6University Hospital Jena, Department of Medicine, Jena, Germany, 7The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 8alesund Hospital, Department of Gastroenterology, Alesund, Norway, 9Hospital Universitario de La Princesa, Department of Gastroenterology, Madrid, Spain, 10Hull and East Yorkshire NHS Trust, Hull and York Medical School, Hull, UK, 11Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland, 12Catholic University of Rome - A. Gemelli Hospital, Department of Internal Medicine and Gastroenterology, Rome, Italy, 13CHU Liege, Sart Tilman, Department of Pediatric Gastroenterology, Liege, Belgium

DOP065: Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trialECCO '18 Vienna
Year: 2018
Authors:

R. Panaccione1*, J.-F. Colombel2, P. Bossuyt3, F. Baert4, T. Vanasek5, A. Danalioglu6, G. Novacek7, A. Armuzzi8, W. Reinisch7, S. Johnson9, M. Buessing9, E. Neimark10, J. Petersson10, A.M. Robinson10, R.B. Thakkar10, W.-J. Lee10, M. Skup10, G. D’Haens11

1University of Calgary, Calgary, Canada, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Imelda General Hospital, Bonheiden, Belgium, 4AZ Delta Roeselare-Menen, Roeselare-Menen, Belgium, 5Hepato-Gastroenterologie HK, s.r.o., Hradec Králové, Czech Republic, 6Bezmialem Vakif University, Istanbul, Turkey, 7Medical University of Vienna, Vienna, Austria, 8Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, 9Medicus Economics LLC, Boston, USA, 10AbbVie Inc., North Chicago, USA, 11IBD Unit, Academic Medical Center, Amsterdam, The Netherlands

DOP066: Developing a core outcome set for fistulising perianal Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

K. Sahnan1*, P.J. Tozer1, S.O. Adegbola1, M.J. Lee2, N. Heywood3, A.G.K. McNair4, D. Hind5, N. Yassin6, A.J. Lobo7, S.R. Brown2, S. Sebastian8, R.K. Phillips1, P.F. Lung9, O.D. Faiz1, K. Crook10, S. Blackwell11, A. Verjee12, A.L. Hart13, N.S. Fearnhead14

1St Mark's Hospital, Colorectal Surgery, London, UK, 2Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Department of Colorectal Surgery, Sheffield, UK, 3University Hospital South Manchester, Department of Colorectal Surgery, Manchester, UK, 4Bristol, School of Social and Community Medicine, Bristol, UK, 5Clinical Trials Research Unit, School of Health and Related Research, Sheffield, UK, Sheffiled, UK, 6Birmingham University Hospitals NHS Trust, Birmingham, UK, 7Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Department of Gastroenterology, Sheffield, UK, 8Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, UK, 9St Mark's Hospital, Gastrointestinal Imaging, London, UK, 10St Mark's Hospital, Department of IBD, London, UK, 11Patient representative, Liverpool, UK, 12Patient representative, London, UK, 13St Mark's Hospital, IBD/Physiology, London, UK, 14Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Colorectal Surgery, Cambridge, UK

DOP067: Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: a comparative effectiveness study of vedolizumab vs. infliximabECCO '18 Vienna
Year: 2018
Authors:

M. Raluy-Callado1, A. Berger2, J.M. Khalid3, H. Patel3*

1Evidera, Real-World Evidence, London, UK, 2Evidera, Real World Evidence, Waltham, MA, USA, 3Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

DOP068: Crohn’s disease decision aid leads to more patients choosing combination therapy in a cluster randomised controlled trialECCO '18 Vienna
Year: 2018
Authors:

C.A. Siegel1*, K.D. Thompson1, L.S. Siegel2, T. MacKenzie3, M.C. Dubinsky4

1Dartmouth-Hitchcock Medical Center, Lebanon, USA, 2Climate Interactive, Hanover, USA, 3Geisel School of Medicine at Dartmouth, Hanover, USA, 4Icahn School of Medicine at Mount Sinai, New York, USA

DOP069: Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trialECCO '18 Vienna
Year: 2018
Authors:

A. Atreja1*, E. Otobo1, E. Szigethy2, H. Shroff1, H. Chang1, L. Keefer1, J. Rogers1, T. Ullman1, J.F. Marion1, B. Cohen1, E. Maser1, S. Itzkowitz1, J.-F. Colombel1, B. Sands1

1Icahn School of Medicine at Mount Sinai, New York, USA, 2University of Pittsburgh, Pittsburgh, USA

DOP070: Development and pilot of an index to identify young people with inflammatory bowel disease at risk of psychological morbidityECCO '18 Vienna
Year: 2018
Authors:

R.T. Lees1*, A.J. Brooks1, G. Rowse2, P. Narula3, P. Norman4, A.J. Lobo1

1Sheffield Teaching Hospitals, Department of Gastroenterology, Sheffield, UK, 2University of Sheffield, Clinical Psychology Unit, Sheffield, UK, 3Sheffield Children’s Hospital, Gastroenterology Department, Sheffield, UK, 4University of Sheffield, Department of Psychology, Sheffield, UK

DOP071: Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALMECCO '18 Vienna
Year: 2018
Authors:

R. Panaccione1*, J.-F. Colombel2, P. Bossuyt3, F. Baert4, T. Vanasek5, A. Danalioglu6, G. Novacek7, A. Armuzzi8, W. Reinisch7, E. Neimark9, J. Petersson9, A.M. Robinson9, R.B. Thakkar9, N. Chen9, M. Skup9, W.-J. Lee9, G. D’Haens10

1University of Calgary, Calgary, Canada, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Imelda General Hospital, Bonheiden, Belgium, 4AZ Delta Roeselare-Menen, Roeselare-Menen, Belgium, 5Hepato-Gastroenterologie HK, s.r.o., Hradec Králové, Czech Republic, 6Bezmialem Vakif University, Istanbul, Turkey, 7Medical University of Vienna, Vienna, Austria, 8Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, 9AbbVie Inc., North Chicago, USA, 10IBD Unit, Academic Medical Center, Amsterdam, The Netherlands

DOP072: Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohortECCO '18 Vienna
Year: 2018
Authors:

N. Plevris, P. Jenkinson, C.S. Chuah, M. Lyons, R. Hall, G. Jones, E. Watson, I. Arnott, C. Lees

NHS Lothian, Gastroenterology, Edinburgh, UK

DOP073: Results of the sixth ECCO Scientific Workshop: The pathogenesis of inflammatory extraintestinal manifestations of inflammatory bowel disease: implications for research, diagnosis, and therapyECCO '18 Vienna
Year: 2018
Authors:

C.R.H. Hedin1*, S.R. Vavricka2, A.J. Stagg3, A. Schoepfer4, T. Raine5, L. Puig6, U. Pleyer7, A. Navarini8, A.E. van der Meulen - de Jong9, J. Maul10, K.H. Katsanos11, A. Kagramanova12, T. Greuter13,14, Y. Gonzalez Lama15, F.A. van Gaalen16, P. Ellul17, J. Burisch18, D. Bettenworth19, M. Becker20, G. Bamias21, F. Rieder22

1Karolinska University Hospital, Gastroenterology Unit, Patient Area Gastroenterology, Dermatovenereology and Rheumatology, Stockholm, Sweden, 2Centre for Gastroenterology and Hepatology, Zurich, Switzerland, 3Barts and The London, Queen Mary's School of Medicine and Dentistry, Centre for Immunobiology, London, UK, 4CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland, 5University of Cambridge, Department of Medicine, Cambridge, UK, 6Universitat Autònoma de Barcelona, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 7Charite - University Hospital Berlin, University Eye Clinic, Uveitis Center, Berlin, Germany, 8University Hospital Zurich, Department of Dermatology, Zurich, Switzerland, 9Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, 10Gastroenterologie am Bayerischen Platz, Berlin, Germany, 11University and Medical School of Ioannina, Department of Internal Medicine I, Division of Gastroenterology and Hepatology, Ioannina, Greece, 12The Loginov Moscow Clinical Scientific Centre, IBD Department, Moscow, Russian Federation, 13Mayo Clinic, Gastroenterology Research Unit, Rochester, MN, USA, 14University of Zurich, Department of Gastroenterology and Hepatology, USZ, Zurich, Switzerland, 15Hospital Universitario Puerta De Hierro, Intestinal Inflammatory Disease Unit / IBD Unit, Gastroenterology and Hepatology Service / Gastroenterology and Hepatology Department, Madrid, Spain, 16Leiden University Medical Center (LUMC), Department of Rheumatology, Leiden, The Netherlands, 17Mater Dei Hospital, Department of Medicine, Division of Gastroenterology, Triq Dun Karm, L-Imsida, Malta, 18North Zealand University Hospital, Department of Gastroenterology and Hepatology, Frederikssund, Denmark, 19University Hospital Münster, Department of Medicine B, Gastroenterology and Hepatology, Münster, Germany, 20Triemli Hospital, Department of Ophthalmology, Zurich, Switzerland, 21Sotiria Hospital, National and Kapodistrian University of Athens, GI Unit, 3rd Academic Dpt. Of Internal Medicine, Athens, Greece, 22Cleveland Clinic Foundation, Department of Gastroenterology and Hepatology, Cleveland, USA

DOP074: IL-33 promotes gut mucosal wound healing by inducing miRNA-320 to stimulate epithelial restitution and repairECCO '18 Vienna
Year: 2018
Authors:

L.R. Lopetuso1,2*, C. De Salvo2, L. Di Martino2, N. Rana2, W. Goodman2, F. Scaldaferri1, A. Armuzzi1, A. Gasbarrini1, T.T. Pizarro2

1Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy, 2Case Western Reserve University, Pathology, Cleveland, USA

DOP075: Colonic gamma delta t-cells respond innately to NKG2D ligands and are grossly dysregulated in active inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

R.J. Dart1,2,3*, P. Vantourout1,2, A. Laing1,2, J. Digby-Bell3, N. Powell3,4, P. Irving3, A. Hayday1,2

1Francis Crick Institute, Immunosurveillance Lab, London, UK, 2King's College London, DIIID, London, UK, 3Guy's and St Thomas Foundation Trust, Department of Gastroenterology, London, UK, 4King's College London, DTIMB, London, UK

DOP076: IL-3 drives IL-10-secreting Tr1 cells to counteract experimental colitisECCO '18 Vienna
Year: 2018
Authors:

S. Zundler*, M. Spocinska, V. Popp, E. Becker, R. Atreya, C. Neufert, I. Atreya, B. Weigmann, M.F. Neurath

University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany

DOP077: Deep immunophenotyping reveals a role for Mucosal Associated Invariant T (MAIT) cells in the response to anti-TNF treatment in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Walshe*, L.A. Elliott, D. Danso-Abeam, G. Cullen, J. Sheridan, H. Mulcahy, E. Ryan, G. Doherty

Centre for Colorectal Disease, St. Vincent's University Hospital, Univsersity College Dublin, Dublin, Ireland

DOP078: Visceral and subcutaneous adipose tissues of Crohn’s disease patients contains bacteriaECCO '18 Vienna
Year: 2018
Authors:

C. Serena1*, M. Terrón-Puig1, E. Maymó-Masip1, M. Queipo-Ortuño2, J. Sabadell-Basallote1, M.M. Rodríguez1, C. Nuñez-Roa1, M. Menacho3, E. Espin4, A. Zorzano5,6, M. Millan7, S. Fernández-Veledo1, J. Vendrell1

1Hospital Universitari de Tarragona Joan XXIII. Institut d´Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, Tarragona, Spain, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain, Tarragona, Spain, 2Servicio de Endocrinología y Nutrición, Campus Teatinos s/n, Hospital Clínico Universitario Virgen de la Victoria, 29010, Málaga, Spain, CIBEROBN, Instituto de Salud Carlos III, Madrid, Spain, 3Hospital Joan XIII, Digestive Unit, Tarragona, Spain, 4Colorectal Surgery Unit, General Surgery Service, Hospital Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain, 5Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain. 6CIBER de Diabetes y Enfermedades Metabolicas Asociadas, Barcelona, Spain. Departamento de Bioquimica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain, 7Hospital Joan XIII, Colorectal Surgery Unit, Tarragona, Spain

DOP079: Heat-shock protein GP96 is essential for self-renewal of the intestinal epithelial barrierECCO '18 Vienna
Year: 2018
Authors:

M. Schwarzfischer1*, Y. Morsy1, K. Atrott1, C. Stanzel1, S. Lang1, G. Rogler1,2, M. Scharl1, M. Spalinger1

1University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 2University Hospital Zurich, Zurich, Switzerland

DOP080: Endoplasmic reticulum stress in bordering epithelium of Crohn’s disease patients with intestinal fibrosisECCO '18 Vienna
Year: 2018
Authors:

S. Hu1*, N. Bletard2, C. Massot1,3, N. Pierre1, F. Quesada Calvo1, G. Paulissen1, N. Smargiasso4, G. Mazzucchelli4, D. Baiwir5, E. De Pauw4, P. Delvenne2, M.-A. Meuwis1,3, E. Louis1,3

1GIGA-R, Uliege, Translational Gastroenterology, Liège, Belgium, 2CHU de Liège, Pathological anatomy, Liège, Belgium, 3CHU de Liège, Hepato-gastroenterology and digestive oncology, Liège, Belgium, 4Uliege,Laboratory of mass spectrometry, Chemistry, Liège, Belgium, 5GIGA proteomic facility, Uliege, GIGA, Liège, Belgium